Once daily insulin detemir in cystic fibrosis with insulin deficiency

被引:38
作者
Hameed, Shihab [1 ,2 ]
Morton, John R. [2 ,3 ]
Field, Penny I. [3 ]
Belessis, Yvonne [2 ,3 ]
Yoong, Terence [3 ]
Katz, Tamarah [3 ]
Woodhead, Helen J. [1 ,2 ]
Walker, Jan L. [1 ,2 ]
Neville, Kristen A. [1 ,2 ]
Campbell, Thomas A. [1 ]
Jaffe, Adam [2 ,3 ]
Verge, Charles F. [1 ,2 ]
机构
[1] Sydney Childrens Hosp, Dept Endocrinol, Randwick, NSW 2031, Australia
[2] Univ New S Wales, Sch Womens & Childrens Hlth, Randwick, NSW, Australia
[3] Sydney Childrens Hosp, Dept Resp Med, Randwick, NSW 2031, Australia
关键词
GLARGINE; ADOLESCENTS; CHILDREN;
D O I
10.1136/adc.2010.204636
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
The aim of this study was to determine if once daily insulin detemir reverses decline in weight and lung function in patients with cystic fibrosis (CF). 12 patients with early insulin deficiency and six with CF related diabetes (aged 7.2-18.1 years) were treated for a median of 0.8 years. Changes in weight and lung function following treatment were compared to pretreatment changes. Before treatment, the change in weight SD score (Delta WtSDS), percentage of predicted forced expiratory volume in 1 s (Delta%FEV1) and percentage of predicted forced vital capacity (Delta%FVC) declined in the whole study population (-0.45 +/- 0.38, -7.9 +/- 12.8%, -5.8 +/- 14.3%) and in the subgroup with early insulin deficiency (-0.41 +/- 0.43, -9.8 +/- 9.3%, -6.8 +/- 10.3%). Following treatment with insulin Delta WtSDS, Delta%FEV1 and Delta%FVC significantly improved in the whole study population (+0.18 +/- 0.29 SDS, p=0.0001; +3.7 +/- 10.6%, p=0.007; +5.2 +/- 12.7%, p=0.013) and in patients with early insulin deficiency (+0.22 +/- 0.31 SDS, p=0.003; +5.3 +/- 11.5%, p=0.004; +5.8 +/- 13.4%, p=0.024). Randomised controlled trials are now needed.
引用
收藏
页码:464 / 467
页数:4
相关论文
共 7 条
[1]   Clinical effects of early treatment with insulin glargine in patients with cystic fibrosis and impaired glucose tolerance [J].
Bizzarri, C ;
Lucidi, V ;
Ciampalini, P ;
Bella, S ;
Russo, B ;
Cappa, M .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2006, 29 (03) :RC1-RC4
[2]   Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial [J].
Danne, Thomas ;
Datz, Nicolin ;
Endahl, Lars ;
Haahr, Hanne ;
Nestoris, Claudia ;
Westergaard, Lisbet ;
Fjording, Marianne Scheel ;
Kordonouri, Olga .
PEDIATRIC DIABETES, 2008, 9 (06) :554-560
[3]   Clinical improvement in cystic fibrosis with early insulin treatment [J].
Dobson, L ;
Hattersley, AT ;
Tiley, S ;
Elworthy, S ;
Oades, PJ ;
Sheldon, CD .
ARCHIVES OF DISEASE IN CHILDHOOD, 2002, 87 (05) :430-431
[4]   Early Glucose Abnormalities in Cystic Fibrosis Are Preceded by Poor Weight Gain [J].
Hameed, Shihab ;
Morton, John R. ;
Jaffe, Adam ;
Field, Penny I. ;
Belessis, Yvonne ;
Yoong, Terence ;
Katz, Tamarah ;
Verge, Charles F. .
DIABETES CARE, 2010, 33 (02) :221-226
[5]   Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes [J].
Heise, T ;
Nosek, L ;
Ronn, BB ;
Endahl, L ;
Heinemann, L ;
Kapitza, C ;
Draeger, E .
DIABETES, 2004, 53 (06) :1614-1620
[6]   Insulin Therapy to Improve BMI in Cystic Fibrosis-Related Diabetes Without Fasting Hyperglycemia Results of the Cystic Fibrosis Related Diabetes Therapy Trial [J].
Moran, Antoinette ;
Tullis, Elizabeth ;
Pekow, Penelope ;
Liou, Theodore G. ;
Grover, Patricia ;
Allen, Holley ;
Zorn, Martha ;
Slovis, Bonnie ;
Pilewski, Joseph .
DIABETES CARE, 2009, 32 (10) :1783-1788
[7]   One-year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements [J].
Mozzillo, Enza ;
Franzese, Adriana ;
Valerio, Giuliana ;
Sepe, Angela ;
De Simone, Ilaria ;
Mazzarella, Gianfranco ;
Ferri, Pasqualina ;
Raia, Valeria .
PEDIATRIC DIABETES, 2009, 10 (03) :162-167